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Consent is obtained from a physician not involved in the study acting on the patients behalf before any trial related procedure are started as this is a trial in an acute setting and eligible patients for this trial will be temporarily incompetent due to acute severe illness and therefore not able to give informed consent. The Investigator will as soon as possible after inclusion of the patient obtain written consent from the patient or proxy consent from both a physician not involved in the study acting on the patient's behalf and next-of-kin. Patients, who, during the course of this trial, become able to give consent, will be asked to participate and give their consent even though a proxy consent is obtained.
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